The following represents disclosure information provided by authors of this abstract. The program committee has reviewed all presenting author disclosure reports, identified potential conflicts of interest, and implemented strategies to manage those areas of conflict, where appropriate. All relationships are considered compensated. Relationships are self-held unless otherwise noted. I = Immediate Family Member, Inst = My Institution   Open Payments is a public database containing information reported by companies about payments made to US-licensed physicians (Open Payments)     Himisha Beltran Consulting or Advisory Role - AstraZeneca; Bayer; Daicchi Sankyo; Merck; Novartis; Pfizer; Sanofi Research Funding - Bristol Myers Squibb Foundation (Inst); Circle Pharma (Inst); Daiichi Sankyo (Inst); Novartis (Inst) Travel, Accommodations, Expenses - Janssen Oncology   Alissa Cooper Honoraria - Ideology Health; Intellisphere; MedStar Health; MJH Life Sciences; Physician's Education Resource, LLC Consulting or Advisory Role - AstraZeneca; Daiichi Sankyo/Astra Zeneca; Gilead Sciences; Regeneron Research Funding - Abbvie (Inst); Amgen (Inst); Merck (Inst); Monte Rosa Therapeutics (Inst); Roche (Inst) Travel, Accommodations, Expenses - Gilead Sciences   Kamya Sankar Consulting or Advisory Role - AstraZeneca Research Funding - Amgen (Inst); Black Diamond Therapeutics (Inst); Genentech/Roche (Inst); Harpoon therapeutics (Inst); Lilly (Inst); Merck (Inst); Summit Therapeutics (Inst)   Benjamin Garmezy Consulting or Advisory Role - Abbvie (Inst); Adaptimmune (Inst); Adicent Therapeutics (Inst); AIQ Global (Inst); Amgen (Inst); Arcus Biosciences (Inst); Arvinas (Inst); AstraZeneca (Inst); AVEO (Inst); Bayer (Inst); Bicycle Therapeutics (Inst); Bristol-Myers Squibb (Inst); Eisai (Inst); EMD Serono (Inst); Exelixis (Inst); Genentech/Roche (Inst); Janssen (Inst); Merck (Inst); Monte Rosa Therapeutics (Inst); Novartis (Inst); Pfizer (Inst); Rondo Therapeutics (Inst); Seagen (Inst); Specialty Networks (Inst); Takeda (Inst); Xencor (Inst) Research Funding - Abbvie (Inst); Accutar Biotech (Inst); Adcentrx Therapeutics (Inst); Adicet Therapeutics (Inst); Amgen (Inst); Arcus Biosciences (Inst); Arvinas (Inst); AstraZeneca (Inst); Avenzo Therapeutics (Inst); AVEO (Inst); Bicycle Therapeutics (Inst); crispr therapeutics (Inst); Eikon Therapuetics (Inst); Envision Pharma Group (Inst); Exelixis (Inst); Flare Therapeutics (Inst); Halda Therapeutics (Inst); Harbour BioMed (Inst); HiberCell (Inst); IDEAYA Biosciences (Inst); Janssen Oncology (Inst); Janux Therapeutics (Inst); Jubilant Therapeutics (Inst); Kineta (Inst); Kinnate Biopharma (Inst); Loxo (Inst); Merck (Inst); MiNK Therapeutics (Inst); Novartis (Inst); Nuvation Bio (Inst); Pfizer (Inst); ProfoundBio (Inst); Roche/Genentech (Inst); Takeda (Inst); Teon Therapeutics (Inst); Tmunity Therapeutics, Inc. (Inst); Xencor (Inst); Zenshine (Inst)   Prantesh Jain Employment - Athenex (I) Consulting or Advisory Role - Amgen; Boehringer Ingelheim; Catalyst Pharmaceuticals Research Funding - Debiopharm Group (Inst); Deciphera (Inst); Harpoon therapeutics (Inst); Iovance Biotherapeutics (Inst); Johnson & Johnson/Janssen (Inst); Merck (Inst); SOPHiA Genetics (Inst); Torl Biotherapeutics (Inst) Patents, Royalties, Other Intellectual Property - Combination of quantitative features from H&E biopsies and CT scans predicts response to chemotherapy and overall survival in Small Cell Lung Cancer (SCLC) US Patent Application No. 63/212,263; Computer extracted features from baseline CT scans predicts response to platinum-based chemotheraphy and is prognostic of overall survival in small cell lung cancer (SCLC) US Patent Application No. 63/212,247 Travel, Accommodations, Expenses - Dava Oncology   Jason Brown Honoraria - Ipsen; Johnson & Johnson/Janssen Consulting or Advisory Role - AstraZeneca; EMD Serono; Johnson & Johnson/Janssen; Pfizer Speakers' Bureau - Merck Research Funding - Bicycle Therapeutics (Inst); Indaptus Therapeutics; Merck (Inst); Novita Pharmaceuticals (Inst); Pfizer (Inst); Roche/Genentech (Inst) Travel, Accommodations, Expenses - Johnson & Johnson/Janssen   Erin Schenk Stock and Other Ownership Interests - Thetis Pharma Honoraria - Beigeneius; Cancer Therapy Advisor; Curio Science; Horizon CME; Ideology Health; Janssen; Johnson & Johnson/Janssen; MECC Global Meetings; MJH Life Sciences; Nuvation Bio; OncLive; OncLive/MJH Life Sciences; Regeneron; Research to Practice Consulting or Advisory Role - AADi; Align2Action; Astellas Pharma; AstraZeneca; BioAtla; CDR-Life; Harpoon therapeutics; IDEOlogy Health; Janssen; Johnson & Johnson/Janssen; Merck; Regeneron; Regeneron; Slingshot Insights; Takeda; The Scienomics Group; Thetis Pharma; Third Bridge; WC Communications; WC-Communications Travel, Accommodations, Expenses - AstraZeneca; CDR-Life   Rachel Sanborn Honoraria - Curio Science; Illumina; OncLive/MJH Life Sciences; Targeted Oncology Consulting or Advisory Role - Abbvie; Amgen; AstraZeneca; BeiGene; Boehringer Ingelheim; Daiichi Sankyo; G1 Therapeutics; GE Healthcare; Gilead Sciences; GlaxoSmithKline; IDEOlogy Health; Illumina; InhibRx; Janssen Oncology; Johnson & Johnson/Janssen; Lilly; Natera; OSE Immunotherapeutics; Pfizer; Rigel; Sanofi/Aventis Research Funding - AstraZeneca; Bristol-Myers Squibb (Inst); Merck Travel, Accommodations, Expenses - Hotspot Therapeutics   Jonathan Thompson Consulting or Advisory Role - GE Healthcare; Regeneron Speakers' Bureau - AstraZeneca Research Funding - Merck (Inst)   Hirva Mamdani Consulting or Advisory Role - ADC Therapeutics (I); ADC Therapeutics (I); AstraZeneca; AstraZeneca; Bristol-Myers Squibb/Medarex; Daiichi Sankyo/Astra Zeneca; Genmab (I) Research Funding - AstraZeneca (Inst); Genentech (I); Genmab (I); Karyopharm Therapeutics (I) Expert Testimony - AstraZeneca (I) Travel, Accommodations, Expenses - AstraZeneca   Soniya Vaidya Employment - Daiichi Sankyo   Douglas Levine Employment - Merck Stock and Other Ownership Interests - Nirova BioSense; Resident Diagnostics Patents, Royalties, Other Intellectual Property - Patent Application US20130078319A1 - Detection of ovarian cancer; Patent application WO2015103431A9 - Compositions and methods for the diagnosis and treatment of ovarian cancers that are associated with reduced SMARCA4 gene expression or protein function   April Wang Employment - Merck Stock and Other Ownership Interests - Merck   Ann Gramza Employment - Merck Stock and Other Ownership Interests - Merck   Rahul Aggarwal Consulting or Advisory Role - Alessa Therapeutics; Amgen; AstraZeneca; Bayer; BioXcel Therapeutics; Boxer Capital; Curio Science; EcoR1 Capital; Exelixis; Flare Therapeutics; Guidepoint Inc; Harpoon therapeutics; Janssen; Merck; MJH Life Sciences; Novartis; PCCTC; Pfizer; Research to Practice; Slingshot Insights; Tersera; Washington Research Foundation Research Funding - Amgen (Inst); AstraZeneca (Inst); Janssen (Inst); Merck (Inst); Novartis (Inst); Xynomic Pharma (Inst); Zenith Epigenetics (Inst) Expert Testimony - University of Utah Health Travel, Accommodations, Expenses - DAVA Oncology